English
简体中文
Total: £ 56.28
Published Date: 2025-04-08 | Pages: 92 | Tables: 100 | Pharma & Healthcare
The global market for CAR-T Therapy For B-Cell Malignancies was valued at US$ 3120 million in the year 2024 and is projected to reach a revised size of US$ 8189 million by 2031, growing at a CAGR of 14.8% during the forecast period.
Chimeric antigen receptor T (CAR-T) cell therapy is an individualized immunotherapy method that uses genetic engineering technology to modify the patient's own T cells to express chimeric antigen receptors (CAR) that can recognize specific antigens on the surface of cancer cells, thereby accurately killing tumor cells. In B-cell malignancies such as B-cell lymphoma, acute lymphoblastic leukemia, multiple myeloma, etc., CAR-T therapy mainly targets B-cell surface antigens (such as CD19, CD20, BCMA) and has become an important treatment option for recurrent or refractory patients.
In recent years, the market size of CAR-T therapy for B-cell malignancies has been continuously expanding. The main driving factors of the market include the increase of the incidence rate of B cell malignant tumors, the progress of related technologies (such as genetic engineering technology, cell production technology, drug delivery system), and the policy support of governments of various countries. The main participants in the market include internationally renowned companies such as Gilead, Roche, Novartis, as well as domestic companies such as Fosun Kite Bio, JW Therapeutics, and CARsgen Therapeutics. These companies are continuously increasing their R&D investment and developing innovative CAR-T therapies to meet clinical needs. The research on CAR-T therapy in B-cell malignancies mainly focuses on improving efficacy and prolonging patient survival. The main bottlenecks in the market are high treatment costs, complex preparation processes, potential side effects, indications limitations, and supply chain issues. The future trend of the industry is the research and development of universal CAR-T, the expansion of application areas (especially in the field of solid tumors), and more policy support. Enterprises will focus on improving the accessibility and safety of CAR-T therapy, developing new target antigens, and promoting the development of combination therapies. In addition, advances in gene editing technology may also bring new opportunities for CAR-T therapy. With the approval of more CAR-T products and the accumulation of clinical data, the CAR-T therapy market for B-cell malignancies is expected to continue to grow in the coming years.
This report aims to provide a comprehensive presentation of the global market for CAR-T Therapy For B-Cell Malignancies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Therapy For B-Cell Malignancies.
The CAR-T Therapy For B-Cell Malignancies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CAR-T Therapy For B-Cell Malignancies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR-T Therapy For B-Cell Malignancies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Roche
Novartis
Regeneron Pharmaceuticals
Bristol Myers Squibb
Celgene
Johnson And Johnson
Bluebird Bio
Kite Pharma
AstraZeneca
Fosun Kite Bio
JW Therapeutics
CARsgen Therapeutics
IMCURE
HEBECELL
Legend Biotech
Beihai Biotechnology
Chongqing Precision Biotech
Segment by Type
Single Target CAR-T
Dual Targets CAR-T
Multi Targets CAR-T
Universal CAR-T
Gene Modified Enhanced CAR-T
Segment by Application
B-Cell Acute Lymphoblastic Leukemia
B-Cell Non-Hodgkin's Lymphoma
Multiple Myeloma
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-T Therapy For B-Cell Malignancies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Single Target CAR-T
1.2.3 Dual Targets CAR-T
1.2.4 Multi Targets CAR-T
1.2.5 Universal CAR-T
1.2.6 Gene Modified Enhanced CAR-T
1.3 Market by Application
1.3.1 Global CAR-T Therapy For B-Cell Malignancies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 B-Cell Acute Lymphoblastic Leukemia
1.3.3 B-Cell Non-Hodgkin's Lymphoma
1.3.4 Multiple Myeloma
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR-T Therapy For B-Cell Malignancies Market Perspective (2020-2031)
2.2 Global CAR-T Therapy For B-Cell Malignancies Growth Trends by Region
2.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 CAR-T Therapy For B-Cell Malignancies Historic Market Size by Region (2020-2025)
2.2.3 CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Region (2026-2031)
2.3 CAR-T Therapy For B-Cell Malignancies Market Dynamics
2.3.1 CAR-T Therapy For B-Cell Malignancies Industry Trends
2.3.2 CAR-T Therapy For B-Cell Malignancies Market Drivers
2.3.3 CAR-T Therapy For B-Cell Malignancies Market Challenges
2.3.4 CAR-T Therapy For B-Cell Malignancies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR-T Therapy For B-Cell Malignancies Players by Revenue
3.1.1 Global Top CAR-T Therapy For B-Cell Malignancies Players by Revenue (2020-2025)
3.1.2 Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Players (2020-2025)
3.2 Global Top CAR-T Therapy For B-Cell Malignancies Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by CAR-T Therapy For B-Cell Malignancies Revenue
3.4 Global CAR-T Therapy For B-Cell Malignancies Market Concentration Ratio
3.4.1 Global CAR-T Therapy For B-Cell Malignancies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy For B-Cell Malignancies Revenue in 2024
3.5 Global Key Players of CAR-T Therapy For B-Cell Malignancies Head office and Area Served
3.6 Global Key Players of CAR-T Therapy For B-Cell Malignancies, Product and Application
3.7 Global Key Players of CAR-T Therapy For B-Cell Malignancies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR-T Therapy For B-Cell Malignancies Breakdown Data by Type
4.1 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size by Type (2020-2025)
4.2 Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Type (2026-2031)
5 CAR-T Therapy For B-Cell Malignancies Breakdown Data by Application
5.1 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size by Application (2020-2025)
5.2 Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)
6.2 North America CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)
6.4 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)
7.2 Europe CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)
7.4 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)
8.2 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2020-2025)
8.4 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)
9.2 Latin America CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)
9.4 Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)
10.2 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)
10.4 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Introduction
11.1.4 Gilead Sciences Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.1.5 Gilead Sciences Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche CAR-T Therapy For B-Cell Malignancies Introduction
11.2.4 Roche Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis CAR-T Therapy For B-Cell Malignancies Introduction
11.3.4 Novartis Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Company Details
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Introduction
11.4.4 Regeneron Pharmaceuticals Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.4.5 Regeneron Pharmaceuticals Recent Development
11.5 Bristol Myers Squibb
11.5.1 Bristol Myers Squibb Company Details
11.5.2 Bristol Myers Squibb Business Overview
11.5.3 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Introduction
11.5.4 Bristol Myers Squibb Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.5.5 Bristol Myers Squibb Recent Development
11.6 Celgene
11.6.1 Celgene Company Details
11.6.2 Celgene Business Overview
11.6.3 Celgene CAR-T Therapy For B-Cell Malignancies Introduction
11.6.4 Celgene Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.6.5 Celgene Recent Development
11.7 Johnson And Johnson
11.7.1 Johnson And Johnson Company Details
11.7.2 Johnson And Johnson Business Overview
11.7.3 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Introduction
11.7.4 Johnson And Johnson Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.7.5 Johnson And Johnson Recent Development
11.8 Bluebird Bio
11.8.1 Bluebird Bio Company Details
11.8.2 Bluebird Bio Business Overview
11.8.3 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Introduction
11.8.4 Bluebird Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.8.5 Bluebird Bio Recent Development
11.9 Kite Pharma
11.9.1 Kite Pharma Company Details
11.9.2 Kite Pharma Business Overview
11.9.3 Kite Pharma CAR-T Therapy For B-Cell Malignancies Introduction
11.9.4 Kite Pharma Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.9.5 Kite Pharma Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Details
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca CAR-T Therapy For B-Cell Malignancies Introduction
11.10.4 AstraZeneca Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.10.5 AstraZeneca Recent Development
11.11 Fosun Kite Bio
11.11.1 Fosun Kite Bio Company Details
11.11.2 Fosun Kite Bio Business Overview
11.11.3 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Introduction
11.11.4 Fosun Kite Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.11.5 Fosun Kite Bio Recent Development
11.12 JW Therapeutics
11.12.1 JW Therapeutics Company Details
11.12.2 JW Therapeutics Business Overview
11.12.3 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Introduction
11.12.4 JW Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.12.5 JW Therapeutics Recent Development
11.13 CARsgen Therapeutics
11.13.1 CARsgen Therapeutics Company Details
11.13.2 CARsgen Therapeutics Business Overview
11.13.3 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Introduction
11.13.4 CARsgen Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.13.5 CARsgen Therapeutics Recent Development
11.14 IMCURE
11.14.1 IMCURE Company Details
11.14.2 IMCURE Business Overview
11.14.3 IMCURE CAR-T Therapy For B-Cell Malignancies Introduction
11.14.4 IMCURE Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.14.5 IMCURE Recent Development
11.15 HEBECELL
11.15.1 HEBECELL Company Details
11.15.2 HEBECELL Business Overview
11.15.3 HEBECELL CAR-T Therapy For B-Cell Malignancies Introduction
11.15.4 HEBECELL Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.15.5 HEBECELL Recent Development
11.16 Legend Biotech
11.16.1 Legend Biotech Company Details
11.16.2 Legend Biotech Business Overview
11.16.3 Legend Biotech CAR-T Therapy For B-Cell Malignancies Introduction
11.16.4 Legend Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.16.5 Legend Biotech Recent Development
11.17 Beihai Biotechnology
11.17.1 Beihai Biotechnology Company Details
11.17.2 Beihai Biotechnology Business Overview
11.17.3 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Introduction
11.17.4 Beihai Biotechnology Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.17.5 Beihai Biotechnology Recent Development
11.18 Chongqing Precision Biotech
11.18.1 Chongqing Precision Biotech Company Details
11.18.2 Chongqing Precision Biotech Business Overview
11.18.3 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Introduction
11.18.4 Chongqing Precision Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
11.18.5 Chongqing Precision Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Single Target CAR-T
Table 3. Key Players of Dual Targets CAR-T
Table 4. Key Players of Multi Targets CAR-T
Table 5. Key Players of Universal CAR-T
Table 6. Key Players of Gene Modified Enhanced CAR-T
Table 7. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2020-2025)
Table 11. Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2026-2031)
Table 13. CAR-T Therapy For B-Cell Malignancies Market Trends
Table 14. CAR-T Therapy For B-Cell Malignancies Market Drivers
Table 15. CAR-T Therapy For B-Cell Malignancies Market Challenges
Table 16. CAR-T Therapy For B-Cell Malignancies Market Restraints
Table 17. Global CAR-T Therapy For B-Cell Malignancies Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global CAR-T Therapy For B-Cell Malignancies Market Share by Players (2020-2025)
Table 19. Global Top CAR-T Therapy For B-Cell Malignancies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy For B-Cell Malignancies as of 2024)
Table 20. Ranking of Global Top CAR-T Therapy For B-Cell Malignancies Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by CAR-T Therapy For B-Cell Malignancies Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of CAR-T Therapy For B-Cell Malignancies, Headquarters and Area Served
Table 23. Global Key Players of CAR-T Therapy For B-Cell Malignancies, Product and Application
Table 24. Global Key Players of CAR-T Therapy For B-Cell Malignancies, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2020-2025)
Table 28. Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2026-2031)
Table 30. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2020-2025)
Table 32. Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2026-2031)
Table 34. North America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)
Table 49. Gilead Sciences Company Details
Table 50. Gilead Sciences Business Overview
Table 51. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product
Table 52. Gilead Sciences Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 53. Gilead Sciences Recent Development
Table 54. Roche Company Details
Table 55. Roche Business Overview
Table 56. Roche CAR-T Therapy For B-Cell Malignancies Product
Table 57. Roche Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 58. Roche Recent Development
Table 59. Novartis Company Details
Table 60. Novartis Business Overview
Table 61. Novartis CAR-T Therapy For B-Cell Malignancies Product
Table 62. Novartis Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. Regeneron Pharmaceuticals Company Details
Table 65. Regeneron Pharmaceuticals Business Overview
Table 66. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product
Table 67. Regeneron Pharmaceuticals Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 68. Regeneron Pharmaceuticals Recent Development
Table 69. Bristol Myers Squibb Company Details
Table 70. Bristol Myers Squibb Business Overview
Table 71. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product
Table 72. Bristol Myers Squibb Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 73. Bristol Myers Squibb Recent Development
Table 74. Celgene Company Details
Table 75. Celgene Business Overview
Table 76. Celgene CAR-T Therapy For B-Cell Malignancies Product
Table 77. Celgene Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 78. Celgene Recent Development
Table 79. Johnson And Johnson Company Details
Table 80. Johnson And Johnson Business Overview
Table 81. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product
Table 82. Johnson And Johnson Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 83. Johnson And Johnson Recent Development
Table 84. Bluebird Bio Company Details
Table 85. Bluebird Bio Business Overview
Table 86. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product
Table 87. Bluebird Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 88. Bluebird Bio Recent Development
Table 89. Kite Pharma Company Details
Table 90. Kite Pharma Business Overview
Table 91. Kite Pharma CAR-T Therapy For B-Cell Malignancies Product
Table 92. Kite Pharma Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 93. Kite Pharma Recent Development
Table 94. AstraZeneca Company Details
Table 95. AstraZeneca Business Overview
Table 96. AstraZeneca CAR-T Therapy For B-Cell Malignancies Product
Table 97. AstraZeneca Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 98. AstraZeneca Recent Development
Table 99. Fosun Kite Bio Company Details
Table 100. Fosun Kite Bio Business Overview
Table 101. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product
Table 102. Fosun Kite Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 103. Fosun Kite Bio Recent Development
Table 104. JW Therapeutics Company Details
Table 105. JW Therapeutics Business Overview
Table 106. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product
Table 107. JW Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 108. JW Therapeutics Recent Development
Table 109. CARsgen Therapeutics Company Details
Table 110. CARsgen Therapeutics Business Overview
Table 111. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product
Table 112. CARsgen Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 113. CARsgen Therapeutics Recent Development
Table 114. IMCURE Company Details
Table 115. IMCURE Business Overview
Table 116. IMCURE CAR-T Therapy For B-Cell Malignancies Product
Table 117. IMCURE Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 118. IMCURE Recent Development
Table 119. HEBECELL Company Details
Table 120. HEBECELL Business Overview
Table 121. HEBECELL CAR-T Therapy For B-Cell Malignancies Product
Table 122. HEBECELL Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 123. HEBECELL Recent Development
Table 124. Legend Biotech Company Details
Table 125. Legend Biotech Business Overview
Table 126. Legend Biotech CAR-T Therapy For B-Cell Malignancies Product
Table 127. Legend Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 128. Legend Biotech Recent Development
Table 129. Beihai Biotechnology Company Details
Table 130. Beihai Biotechnology Business Overview
Table 131. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product
Table 132. Beihai Biotechnology Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 133. Beihai Biotechnology Recent Development
Table 134. Chongqing Precision Biotech Company Details
Table 135. Chongqing Precision Biotech Business Overview
Table 136. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product
Table 137. Chongqing Precision Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)
Table 138. Chongqing Precision Biotech Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
Table 142. Authors List of This Report
List of Figures
Figure 1. CAR-T Therapy For B-Cell Malignancies Picture
Figure 2. Global CAR-T Therapy For B-Cell Malignancies Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global CAR-T Therapy For B-Cell Malignancies Market Share by Type: 2024 VS 2031
Figure 4. Single Target CAR-T Features
Figure 5. Dual Targets CAR-T Features
Figure 6. Multi Targets CAR-T Features
Figure 7. Universal CAR-T Features
Figure 8. Gene Modified Enhanced CAR-T Features
Figure 9. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global CAR-T Therapy For B-Cell Malignancies Market Share by Application: 2024 VS 2031
Figure 11. B-Cell Acute Lymphoblastic Leukemia Case Studies
Figure 12. B-Cell Non-Hodgkin's Lymphoma Case Studies
Figure 13. Multiple Myeloma Case Studies
Figure 14. Others Case Studies
Figure 15. CAR-T Therapy For B-Cell Malignancies Report Years Considered
Figure 16. Global CAR-T Therapy For B-Cell Malignancies Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global CAR-T Therapy For B-Cell Malignancies Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region: 2024 VS 2031
Figure 19. Global CAR-T Therapy For B-Cell Malignancies Market Share by Players in 2024
Figure 20. Global CAR-T Therapy For B-Cell Malignancies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by CAR-T Therapy For B-Cell Malignancies Revenue in 2024
Figure 22. North America CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)
Figure 24. United States CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)
Figure 28. Germany CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Share by Region (2020-2031)
Figure 36. China CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)
Figure 44. Mexico CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)
Figure 48. Turkey CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Gilead Sciences Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 52. Roche Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 53. Novartis Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 54. Regeneron Pharmaceuticals Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 55. Bristol Myers Squibb Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 56. Celgene Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 57. Johnson And Johnson Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 58. Bluebird Bio Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 59. Kite Pharma Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 60. AstraZeneca Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 61. Fosun Kite Bio Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 62. JW Therapeutics Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 63. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 64. IMCURE Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 65. HEBECELL Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 66. Legend Biotech Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 67. Beihai Biotechnology Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 68. Chongqing Precision Biotech Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
